New treatment approaches in sepsis;Neue therapieansätze bei sepsis

Zentralblatt fur Chirurgie

Volumn 127, Issue 3, 2002, Pages 174-179

  Bloos, F ^a   Reinhart, Konrad ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

ATIII; Hydrocortisone; Protein C; Sepsis; TNF antibodies

Indexed keywords

AFELIMOMAB; ANTITHROMBIN III; BAY 1351; CB 006; GRANULOCYTE COLONY STIMULATING FACTOR; HYBRID PROTEIN; HYDROCORTISONE; IMMUNOMODULATING AGENT; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MONOCLONAL ANTIBODY; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN C; PROTEIN P55; PROTEIN P75; STEROID; THROMBOCYTE ACTIVATING FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ARTICLE; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DOSE RESPONSE; HEMOFILTRATION; HUMAN; IMMUNOMODULATION; MORTALITY; SEPSIS; SEPTIC SHOCK; SURVIVAL RATE; TREATMENT OUTCOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; HUMANS; HYDROCORTISONE; PROTEIN C; RECEPTORS, INTERLEUKIN-1; RECEPTORS, TUMOR NECROSIS FACTOR; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT OUTCOME;

EID: 0036215806     PISSN: 0044409X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-24252     Document Type: Article

References (57)

1. Double-blind randomized controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock
2. Efficacy and safety of monoclonal antibody to human tumor necrosis factor α in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial
3. p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock
4. Definition for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis
5. Effects of the combination of hydrocortisone (HC) -fludrocortisone (FC) on mortality in septic shock
6. Effects of ibuprofen on the physiology and survival of hypothermic sepsis
7. The effects of ibuprofen on the physiology and survival of patients with sepsis
8. Passive Immunization against cachectin/tumor necrosis factor protects mice from lethal effects of endotoxin
9. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock
10. Adjunctive sepsis therapies: Glucocorticoids - What is proven?
11. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome
12. Increase in National Hospital Discharge Survey rates for septicemia - United States, 1979-87
13. INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis
14. Plasma tumor necrosis factor and mortality in critically ill septic patients
15. Phase 1 safety trial of Filgrastim (r-metHuG-CSF) in non-neutropenic patients with severe community-acquired pneumonia
16. Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial
17. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: A randomized, double-blind, placebo-controlled, multicenter clinical trial
18. CDP571, a humanized antibody to human tumor necrosis factor-alpha: Safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock
19. Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute-phase proteins during the treatment of severe sepsis in humans
20. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein
21. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis
22. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open-label, placebo-controlled multicenter trial
23. Protein C levels as a prognostic indicator of outcome in sepsis and related diseases
24. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies
25. Doubleblind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation
26. Efficacy and safety of recombinant human activated protein C for severe Sepsis
27. Plasma degradation of platelet-activating factor in severily ill patients with clinical sepsis
28. Sepsis und septischer schock - Definition und epidemiologie
29. Safety of a low-dosage Filgrastim (rhG-CSF) treatment in non-neutropenic surgical intensive care patients with an inflammatory process
30. A pilot study of antithrombin replacement in intensive care management: The effects on mortality, coagulation and renal function
31. Cytokine removal and cardiovascular hemodynamics in septic patients with continuous venovenous hemofiltration
32. Effect of hemofiltration on hemodynamics and systemic concentrations of anaphylatoxins and cytokines in human sepsis
33. Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock
34. Source control in the management of sepsis
35. Loss of vascular responsiveness induced by endotoxin involves L-arginine pathway
36. Mechanismen der inflammatorischen wirtsantwort bei schweren infektionen
37. Coagulation/fibrinolysis balance in septic shock related to cytokines and clinical state
38. Supportive behandlungsstrategien
39. Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications
40. A randomized, double-masked, placebo-controlled trial of recombinant granulocyte colony-stimulating factor administration to preterm infants with the clinical diagnosis of early-onset sepsis
41. The therapeutic rationale for the use of Antithrombin-Ill in sepsis
42. Antithrombin-Ill in the treatment of severe sepsis: The result of a phase III multicenter clinical trial
43. Neutralization of TNF by a monoclonal antibody improves survival and reduces organ dysfunction in human sepsis: Results of the MONARCS trial
44. Impact of immunomodulating therapy on morbidity in patients with severe sepsis
45. Vasoactive drug therapy in sepsis
46. Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study
47. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock; A multicenter, randomized, placebo-controlled, dose-ranging study
48. Epidemiology of sepsis syndrome in 8 academic medical centers
49. Plasmapheresis combined with continuous venovenous hemofiltration in surgical patients with sepsis
50. Activated protein C inhibits tumor necrosis factor and macrophage migration inhibitory factor production in monocytes
51. Pattern of soluble TNF receptors I and II in sepsis
52. Fluid therapy in sepsis
53. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis
54. Coagulation disorders in septic shock
55. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia
56. Endotoxin, interleukin-1, and tumor necrosis factor cause neutrophil-dependent microvascular leackage in postcapillary venules
57. Antiinflammatory therapies to treat sepsis and septic shock - A reassessment